Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Wegener's granulomatosis

G S Hoffman1

  • 1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, OH 44195.

Current Opinion in Rheumatology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Wegener's granulomatosis, characterized by relapses and anti-proteinase 3 antibodies, often leads to long-term complications. Research is exploring new therapies beyond cyclophosphamide and glucocorticoids to improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Establishing the Feasibility of Face Transplantation in Granulomatosis With Polyangiitis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Giant cell arteritis: Commentary on recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).

La Revue de medecine interne·2016
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same author

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis and rheumatism·2013

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Wegener's granulomatosis is a chronic, relapsing disease associated with anti-proteinase 3 antibodies.
  • Current treatments (cyclophosphamide, glucocorticoids) induce remission but often result in relapse and permanent morbidity.
  • There is a need for more effective and less toxic therapeutic strategies.

Purpose of the Study:

  • To review the current understanding of Wegener's granulomatosis, focusing on its relapsing nature and antibody association.
  • To discuss ongoing research into alternative and novel therapeutic approaches.
  • To highlight the challenges in developing improved treatments, particularly the lack of an animal model.

Main Methods:

  • Literature review of Wegener's granulomatosis, its treatment, and emerging research.

Related Experiment Videos

  • Analysis of the role of anti-proteinase 3 antibodies in disease pathogenesis.
  • Evaluation of preliminary studies on alternative therapies like methotrexate and biologics.

    • Main Results:

    • Conventional therapy achieves remission in most but is followed by relapse in at least 50% of patients.
    • Most patients suffer permanent morbidity due to the disease or its treatment.
    • Preliminary studies show potential for other agents, but definitive proof is lacking.

    Conclusions:

    • Improved therapies are needed due to the limitations of current treatments for Wegener's granulomatosis.
    • Understanding the pathogenic role of anti-proteinase 3 antibodies is crucial for developing targeted treatments.
    • The absence of a suitable animal model hinders research progress and validation of therapeutic strategies.